Smokers in the United States could soon have a new, plant-derived option for quitting if federal regulators approve cytisinicline, an alkaloid extracted from the seeds of the golden rain tree. Two Phase 3 clinical trials, ORCA-2 and ORCA-3, each showed that the compound helped significantly more adults stop smoking than a placebo, using carbon monoxide breath tests to confirm abstinence. A separate, smaller trial tested the same drug for vaping cessation, but the path to market for cigarette smokers appears further along, backed by larger datasets and stricter trial designs.
Why a plant alkaloid is drawing FDA attention right now
The regulatory stakes are straightforward. Existing prescription options for smoking cessation in the U.S. are limited to a handful of drugs, including varenicline and bupropion, along with nicotine replacement therapies. Cytisinicline acts on the same nicotinic acetylcholine receptors as varenicline but is derived from a botanical source that has been used in parts of Central and Eastern Europe for decades. What changed is that the compound now has two U.S.-based, double-blind, placebo-controlled Phase 3 trials behind it, both published in JAMA, giving regulators a modern evidence package to evaluate.
The distinction between the smoking and vaping data matters for anyone watching the approval timeline. ORCA-2 and ORCA-3 were each powered as full-scale Phase 3 studies with prespecified primary endpoints focused on combustible tobacco users. The ORCA-V1 vaping cessation trial, published in JAMA Network Open, was designed as a smaller exploratory study in adults using nicotine e-cigarettes. That difference in trial size and design means the smoking indication carries the stronger statistical foundation, making it the likelier candidate for an initial regulatory filing.
ORCA-2 and ORCA-3 trial results published in JAMA
The ORCA-2 trial, registered on ClinicalTrials.gov as NCT04576949, randomized adult smokers across U.S. sites into three arms: a 6-week cytisinicline regimen, a 12-week cytisinicline regimen, and placebo. Abstinence was not self-reported alone. Investigators used exhaled carbon monoxide biochemical verification to confirm whether participants had actually stopped smoking, a standard that reduces the risk of inflated quit rates.
In the published analysis of the ORCA‑2 cohort, both active treatment durations produced higher continuous abstinence rates than placebo during the final weeks of treatment. Participants received brief behavioral support alongside medication, mirroring how the drug might be used in primary care or smoking cessation clinics. The trial also tracked withdrawal symptoms and craving scores, offering regulators a window into how tolerable the regimen may be for typical smokers.
The ORCA-3 replication trial, registered as NCT05206370, repeated the same double-blind, placebo-controlled structure and confirmed statistically significant efficacy for both the 6-week and 12-week courses. In the ORCA‑3 report, investigators again used carbon monoxide verification and similar counseling intensity, and they observed consistent effect sizes relative to placebo. Replication is a high bar in clinical research. Having two independent Phase 3 studies reach the same conclusion strengthens the case that the results were not a statistical fluke and that the benefit is robust across different study populations and sites.
The compound’s track record extends further back. A placebo-controlled trial of cytisine published in the New England Journal of Medicine, conducted in smokers outside the United States, showed higher sustained abstinence than placebo at 12 months. That earlier work provided the scientific rationale for the ORCA program and demonstrated that the quit-rate advantage could persist well beyond the treatment window, at least under trial conditions with structured follow-up.
How cytisinicline compares with existing therapies
For clinicians, the key question is not just whether cytisinicline works, but how it fits alongside existing tools. Varenicline is also a partial agonist at nicotinic acetylcholine receptors and has long been considered one of the most effective pharmacologic options for smoking cessation. Bupropion, an antidepressant with dopaminergic and noradrenergic activity, offers a different mechanism and can be useful for some patients, particularly those with coexisting mood disorders. Nicotine replacement therapy, delivered via patches, gum, lozenges, or inhalers, provides a more gradual taper of nicotine exposure.
Cytisinicline’s mechanism overlaps with varenicline, but its dosing schedule and side-effect profile differ in the available trials. ORCA-2 and ORCA-3 used a three-times-daily oral regimen, which may pose adherence challenges compared with once-daily alternatives, yet the shorter 6-week course could appeal to patients wary of long-term medication use. Reported adverse events in the Phase 3 studies were generally mild to moderate, with gastrointestinal symptoms and sleep disturbances among the more common complaints, though cross-trial comparisons must be made cautiously.
Cost and access could also shape cytisinicline’s role if it reaches the market. In some countries where related plant-derived compounds have been used for decades, affordability has been a major advantage over branded medications. Whether that pattern will hold in the U.S. will depend on pricing decisions, insurance coverage, and whether payers view cytisinicline as a first-line or second-line therapy after failure of existing agents.
What the vaping data can – and cannot – tell us
Interest in cytisinicline is not limited to combustible cigarettes. The ORCA-V1 trial tested the same molecule in adults who primarily used nicotine e-cigarettes, reflecting a growing population of people addicted to vaping rather than traditional tobacco. That study suggested a potential benefit for e-cigarette users trying to quit, but it was explicitly designed as a smaller, exploratory effort rather than a pivotal Phase 3 trial.
The vaping data therefore function more as a signal than as definitive evidence. The sample size was modest, and the trial was not powered to the same statistical thresholds as ORCA-2 and ORCA-3. For regulators, that means the smoking indication is far more mature from an evidentiary standpoint. Any eventual application for a vaping cessation label would likely require additional, larger studies with prespecified endpoints and longer follow-up.
Gaps in the evidence that regulators still need to resolve
Strong trial results do not guarantee approval. Several questions remain open, and the publicly available clinical records do not yet answer all of them. No FDA briefing documents or advisory committee transcripts tied to cytisinicline have appeared in the primary registry records for the ORCA program. Without those documents, outside observers cannot assess how agency reviewers are interpreting the safety and efficacy data or whether they have flagged concerns about specific subgroups or adverse events.
Long-term cardiovascular safety data beyond the follow-up windows of the published trials are also absent from the peer-reviewed literature and registry summaries. Varenicline, the most pharmacologically similar approved drug, faced years of post-marketing safety scrutiny related to neuropsychiatric and cardiovascular signals. Regulators will almost certainly want to understand whether cytisinicline carries similar risks, and the current evidence base does not fully address that question. Extended observational follow-up or dedicated safety studies may be required either before or soon after any approval.
Real-world adherence is another blind spot. Clinical trials provide structured behavioral support, frequent contact with study staff, and incentives to remain engaged-conditions that typical patients do not experience. How well smokers stick with a three-times-daily, 6-week or 12-week cytisinicline regimen outside a controlled research setting, and whether quit rates hold up in routine practice, is unknown based on the available published data. Health systems may need implementation studies to understand how best to integrate the drug into cessation programs.
What to watch next
For the millions of Americans still smoking combustible cigarettes, the practical next step is to watch for signs that the regulatory review is progressing, such as an FDA advisory committee meeting notice or confirmation that a new drug application has been accepted for full review. Either development would indicate that the agency has moved from data gathering to active evaluation of cytisinicline’s risk–benefit profile.
In the meantime, the two Phase 3 ORCA trials provide a clearer picture than has existed for any new smoking cessation medication in years: a plant-derived partial agonist with replicated efficacy against placebo, a tolerable side-effect profile in controlled settings, and plausible but still incomplete evidence on long-term safety and real-world performance. Whether that package is enough for approval-and how quickly the drug might reach clinicians and patients-now depends less on laboratory science and more on the deliberations inside the FDA’s walls.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
